Decode your diagnosis.

A diagnosis of an upper GI or HPB cancer arrives wrapped in unfamiliar words. This page translates them, walks you through every test and document you will be handed, and gives you the questions to ask in the room.

Tap a word to translate it

HPB

Hepato-pancreato-biliary. The liver, pancreas and bile ducts, the organs that work together to digest food. Cancers in this region are grouped together because they share anatomy and are operated on by the same specialist teams.

in your referral letter and at your first appointment.

HPB Hepato-pancreato-biliary. The liver, pancreas and bile ducts, the organs that work together to digest food.
Adenocarcinoma The most common type of cancer in this region. It starts in the glandular cells that line the inside of an organ.
Neoadjuvant Treatment given before surgery to shrink the tumour.
MDT Multidisciplinary team. The specialists who review your case together.
Margin The edge of the tissue removed in surgery. A clear margin is a good sign.
Resectable Able to be removed by surgery.
Stent A small tube placed in a blocked duct to keep it open.
Biopsy A small tissue sample taken for testing.
FBC Full blood count. Measures your red cells, white cells and platelets.
Neutrophils The white cells that fight infection. Watched closely during chemotherapy.
LFTs Liver function tests. Show how well your liver and bile ducts are working.
eGFR A measure of how well your kidneys are filtering.
INR How quickly your blood clots. Checked before surgery.
Jaundice Yellowing of the skin and eyes when a bile duct is blocked. Often relieved quickly with a stent.
Port A small device under the skin of the chest, connected to a vein, so chemotherapy does not need repeated needle sticks.
Palliative Care focused on comfort and quality of life. It can run alongside active treatment from the start.
Know your diagnosis

The cancers we focus on.

These are shorthand terms your care team will use often. Knowing what they refer to makes every appointment easier to follow. Each of these cancers begins in a different organ, but they share one thing: they are among the hardest to detect early, which is why research and specialist care matter so much.

Upper GI (upper gastrointestinal) refers to the upper part of the digestive system: the oesophagus (the food pipe), the stomach, and the first part of the small bowel (the duodenum). Food travels down the oesophagus, is broken down in the stomach, and passes into the duodenum, where digestion continues.

HPB stands for hepato-pancreato-biliary. Hepato means the liver, the body's chemical factory. Pancreato means the pancreas, which produces digestive enzymes and hormones like insulin. Biliary refers to the bile ducts and gallbladder, the drainage network that carries bile into the bowel to help digest fat. These organs sit close together and share a blood supply and drainage routes, which is why cancers in this region are grouped, studied and operated on together. In fact, the branching bile-duct network is so tree-like that surgeons call it the biliary tree, the very shape that inspired our logo.

Oesophagus

Oesophageal cancer

Begins in the lining of the food pipe. The two main types are adenocarcinoma (often linked to long-standing reflux) and squamous cell carcinoma. Early changes can be subtle, such as difficulty swallowing or persistent heartburn.

Also called: cancer of the gullet, oesophageal adenocarcinoma

Read the oesophageal cancer guide
Stomach

Stomach (gastric) cancer

Begins in the stomach, most often in the inner lining. Symptoms such as indigestion, feeling full quickly or unexplained weight loss are easy to mistake for everyday complaints, which is why it is often found at a later stage.

Also called: gastric cancer, gastric adenocarcinoma

Read the stomach cancer guide
Pancreas

Pancreatic cancer

Begins in the pancreas, most commonly in the ducts that carry digestive enzymes. It tends to grow quietly and spread early, so research into earlier detection, such as our pancreatic cyst registry, is a priority.

Also called: pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma

Read the pancreatic cancer guide
Liver

Liver cancer

Primary liver cancer begins in the liver itself, most often in people with long-standing liver disease or cirrhosis. The liver can also be a site where cancers from elsewhere spread, which your team will distinguish carefully.

Also called: hepatocellular carcinoma (HCC)

Read the liver cancer guide
Bile ducts & gallbladder

Biliary tract cancer

Begins in the bile ducts (cholangiocarcinoma) or the gallbladder. These cancers can block the flow of bile, causing jaundice, a yellowing of the skin and eyes, which is often the first noticeable sign.

Also called: cholangiocarcinoma, gallbladder cancer

Read the biliary tract cancer guide
Where the oesophagus meets the stomach

Gastro-oesophageal junction cancer

Begins where the oesophagus joins the stomach, an area often abbreviated as the GOJ or OG junction. It is treated by the same specialist teams as oesophageal and stomach cancers.

Also called: GOJ cancer, junctional adenocarcinoma

Read the junction cancer guide
The road ahead

Your journey, step by step.

The weeks after a referral can feel like a blur of appointments and acronyms. They are not random. They follow a sequence that nearly everyone moves through, and knowing where you are in it makes each step less frightening. Here is the whole arc, with the words you are likely to hear at each stop.

1

Referral & first appointment

Week 1

Your GP refers you to a specialist with an interest in upper GI or HPB cancers, usually a surgeon or an oncologist. This first visit is mostly conversation: your history, your symptoms, and a plan for the tests ahead. Bring someone with you, and a list of your medications.

You’ll hearHPBconsultantspecialist
Who’s who in hospital →
2

Scans & imaging

Weeks 1 to 2

A series of scans builds a picture of exactly where things are. A CT is usually first, and an MRI, PET scan or endoscopic ultrasound may follow. Each one answers a specific question, so the number of scans is a sign of thoroughness, not of bad news.

You’ll hearcontraststagingresectable
Tests, explained →
3

Biopsy & pathology

Weeks 2 to 3

A small tissue sample is taken and examined under a microscope. For most cancers it confirms the diagnosis and names the cancer type exactly. Some cancers, such as liver cancer in a cirrhotic liver, can be diagnosed from characteristic imaging without a biopsy. The wait for results, usually five to ten working days, is often the hardest stretch of the whole journey.

You’ll hearadenocarcinomagradebiopsy
Tests, explained →
4

The MDT meeting

Weeks 2 to 4

Your case is reviewed by the whole team at once: surgeons, oncologists, radiologists and pathologists in one room, rather than one doctor at a time. The plan you receive has already been stress-tested by the people who will deliver it.

You’ll hearMDTmultidisciplinary team
The MDT meeting →
5

Treatment planning

Weeks 3 to 5

Your doctor walks you through the recommended plan and the alternatives, including what happens with each option and with none. This is the appointment to bring your questions, and a notebook or a voice recording, because you will not remember everything.

You’ll hearneoadjuvantchemotherapyclinical trial
Questions to ask →
6

Treatment

From week 4

Treatment may be surgery, chemotherapy, radiotherapy, or a combination, sometimes given in a specific order. Your team monitors you closely with regular blood tests and adjusts the plan as they go, so you are never simply left to get on with it.

You’ll hearportcycleFBCneutrophils
Side effects →
7

Follow-up & monitoring

Ongoing

After active treatment you move to regular check-ups, blood tests and scans. The goal shifts to watching for any return and supporting your recovery, for as long as you need it. Survivorship care is part of your treatment, not an afterthought.

You’ll hearremissionrecurrencetumour markers
Routine monitoring →
A note on timing

Every journey is different, and not everyone has every step. Some people go straight to surgery, others start with chemotherapy. The timeframes above are typical, not a schedule, and your team will give you your own. If the waiting between steps is wearing you down, tell your clinical nurse consultant. Being honest about how it is affecting you is part of your care too.

Every test, explained

What they are looking for, and why.

You will be sent for a series of tests in the first weeks after a diagnosis. None of them are random. Each one answers a specific question your team needs answered before they can plan your care. Open any test below to see what it is, why it is done, what it feels like, and when results typically arrive.

Blood tests

Tumour markers (CA19-9, CEA, AFP)Blood

What it is: Proteins that some cancers release into the blood. CA19-9 is most often used for pancreatic and biliary cancers, CEA for stomach and bowel cancers, and AFP for liver cancer.

Why it is done: To support the diagnosis, and more importantly to track how well treatment is working over time. A falling number is generally a good sign.

What it feels like: A routine blood draw.

When results arrive: Usually within a few days.

A raised marker alone does not diagnose cancer, and a normal marker does not rule it out. It is one piece of the puzzle, not the answer.

Looking for FBC or LFTs? They are routine monitoring tests, so they are explained in depth in Routine monitoring tests, along with every other blood test repeated during treatment and follow-up.

Scans and imaging

CT scanImaging

What it is: A series of detailed X-ray images assembled into a three-dimensional picture of your body.

Why it is done: The main scan for finding a tumour, measuring its size, and checking whether it has spread. It is the starting point for most treatment planning.

What it feels like: You lie still on a table that slides through a wide ring for a few minutes. You may receive contrast dye through a small cannula, which can cause a brief warm feeling.

When results arrive: A radiologist reports the scan, usually within a few days.

MRI and MRCPImaging

What it is: Detailed images made with magnets and radio waves, without radiation. MRCP is a special MRI sequence that pictures the bile ducts and pancreatic duct in particular.

Why it is done: To look closely at the liver, pancreas and bile ducts, especially when a CT is not clear enough.

What it feels like: You lie still inside a tunnel for 20 to 45 minutes. It is noisy, so you are given headphones. Tell the team beforehand if you are claustrophobic.

When results arrive: Usually within a few days.

PET scanImaging

What it is: A scan that shows where cells in the body are most active, using a small amount of a radioactive sugar.

Why it is done: To check whether cancer has spread beyond what a CT can show, before a big operation is planned.

What it feels like: An injection, then about an hour of quiet rest, then a 20 to 30 minute scan.

When results arrive: Usually within a few days.

Endoscopy (gastroscopy)Procedure

What it is: A thin, flexible camera passed through the mouth into the oesophagus and stomach.

Why it is done: To look directly at the lining and take biopsies of anything suspicious. It is how most oesophageal and stomach cancers are first confirmed.

What it feels like: Usually done with sedation or a numbing throat spray. It is brief and uncomfortable rather than painful, and with sedation most people remember little of it.

When results arrive: The biopsy goes to the lab; results typically take 5 to 10 working days.

Endoscopic ultrasound (EUS)Procedure

What it is: An endoscope with a small ultrasound probe on its tip, so the scan happens from inside the body, right next to the pancreas.

Why it is done: To see the pancreas and nearby structures in fine detail, and to guide a needle biopsy of a mass.

What it feels like: Like an endoscopy, with sedation.

When results arrive: The biopsy result typically takes 5 to 10 working days.

ERCPProcedure

What it is: An endoscope used to inject dye into the bile ducts so they show up on X-ray.

Why it is done: Most often to place a stent that relieves a blocked bile duct and the jaundice it causes. Sometimes to collect brushings of cells for testing.

What it feels like: Done with sedation. You may have a sore throat afterwards.

When results arrive: The stent works immediately; any cell samples take about a week.

Biopsy and anatomical pathology

BiopsyTissue sample

What it is: A small sample of tissue taken from a suspicious area, either with a needle through the skin or through an endoscope.

Why it is done: It is the only way to know for certain whether something is cancer, and exactly what type. Treatment almost never begins without one.

What it feels like: Usually done with local anaesthetic and often sedation. You may feel pressure rather than pain.

When results arrive: Typically 5 to 10 working days.

What the lab does with your sample (anatomical pathology)Laboratory

What it is: Your sample is preserved, sliced thinner than paper, stained, and examined under a microscope by a specialist doctor called a pathologist.

Why it is done: To identify the cancer type, its grade, and other features that guide treatment. The pathologist may also run special stains and molecular tests on the same sample.

What it feels like: Nothing happens to you during this stage. This is the "waiting" period.

When results arrive: Usually 5 to 10 working days. Complex cases, or samples that need extra stains and molecular tests, can take longer. A longer wait usually means the lab is being thorough, not that the news is worse.

Genetic and molecular tests

Tumour profiling (molecular or genomic testing)On the tumour

What it is: Testing the DNA of the cancer itself, using tissue from your biopsy or surgery, to look for specific mutations that can be targeted by drugs.

Why it is done: To match you to a targeted therapy or immunotherapy, or to a clinical trial. It looks at the cancer's genes, not the genes you were born with.

What it feels like: Nothing extra. It uses tissue that has already been taken.

When results arrive: Usually 2 to 4 weeks.

Not everyone needs every test below. Which panel your team uses depends on the type of cancer and what the standard tests have already shown. Each of these tests reads the cancer's own DNA to look for changes that can be matched to a targeted treatment or a clinical trial. The exception is the inherited (germline) test at the end of this section, which reads the DNA you were born with.

Pancreatic, stomach and oesophageal cancer panelOn the tumour

What it is: A broader genomic test that reads around 110 genes in the cancer's DNA. As well as small spelling changes in the genes, it looks for extra or missing copies of genes (copy number changes) and checks MSI status, a measure of how well the tumour can repair its own DNA.

Why it is done: To find targetable changes and immunotherapy markers that can guide treatment or open up clinical trial options for pancreatic, stomach and oesophageal cancers.

What it feels like: Nothing extra. It uses tissue that has already been taken.

When results arrive: Usually 2 to 4 weeks.

Bile duct, gallbladder and liver cancer panelOn the tumour

What it is: A targeted genomic test that reads around 45 genes, checking for specific mutations such as IDH1 and FGFR2, and for gene fusions, where two genes join together abnormally.

Why it is done: Bile duct cancers (cholangiocarcinoma) in particular can carry IDH1 or FGFR2 changes that may be matched to targeted drugs or clinical trials.

What it feels like: Nothing extra. It uses tissue that has already been taken.

When results arrive: Usually 2 to 4 weeks.

Liquid biopsy (ctDNA)Blood sample

What it is: A blood test that looks for tiny fragments of tumour DNA (ctDNA) circulating in the bloodstream. It is used when a tissue sample is not available or not sufficient for genomic testing.

Why it is done: To look for targetable mutations when tissue cannot be obtained. It is not a replacement for a tissue biopsy, rather an alternative when tissue is not an option.

What it feels like: A normal blood draw.

When results arrive: Your team will tell you when to expect them.

Comprehensive genomic profiling (CGP)On the tumour

What it is: The most extensive genomic test. It reads hundreds of genes (around 650), looking for mutations, copy number changes, gene fusions, MSI status and TMB, the tumour mutational burden.

Why it is done: Used when a standard panel has not answered the question, for rarer situations, or to look for clinical trial options across many genes at once.

What it feels like: Nothing extra. It uses tissue that has already been taken.

When results arrive: Usually several weeks, as it is a more extensive test.

The exact panel used varies between laboratories and hospitals. Your team will explain what they tested for and why, and what the results mean for your options.

Inherited (germline) genetic testingOn you

What it is: A blood or saliva test that looks at the DNA you were born with, for inherited changes such as BRCA1, BRCA2 or the Lynch syndrome genes.

Why it is done: To find out whether the cancer may run in your family, and what that means for your relatives. It can also open up targeted treatment options for you.

What it feels like: A blood draw or a saliva sample. It is usually arranged through a genetic counsellor or a family cancer clinic, with proper support before and after.

When results arrive: Usually 2 to 4 weeks.

Less common tests

Bone marrow testRarely needed

What it is: A small sample of the spongy tissue inside bone, usually taken from the back of the hip under local anaesthetic.

Why it is done: This is not a routine test for upper GI or HPB cancers. It is used when there is a specific reason, such as unexplained changes in your blood counts, or a question about whether the bone marrow is involved.

What it feels like: A brief ache or pressure, done with local anaesthetic and sometimes sedation.

When results arrive: Usually within a week.

If your team has suggested one, ask them why. It usually means they are being thorough, not that things are worse.

Timing varies. The timeframes above are typical, not guaranteed. Every hospital and every sample is different. If a result is taking longer than you were told, it is always reasonable to call your clinical nurse consultant and ask.

The tests that track you

Routine blood tests while you are monitored.

Once you are in treatment or on follow-up, you will have blood tests at regular intervals. These are not the tests that found the cancer. They are the tests that watch how your body is travelling, and catch problems early. Knowing what each one measures takes the mystery out of the form you are handed every visit.

Monitoring is different to diagnosis. Diagnostic tests, such as tumour markers and biopsies, are done once to find and name the cancer. Monitoring tests are repeated to answer a simpler question: is your body coping with treatment, and is anything drifting out of range? A single result is rarely a verdict. Your team reads the trend over time, against your own baseline.

What is on a typical monitoring panel

Full blood count (FBC)Blood

What it measures: Your red blood cells (haemoglobin), white blood cells and platelets, all counted in one go. It is the most common monitoring test you will have.

Why it is repeated: Chemotherapy temporarily suppresses the bone marrow, where blood cells are made. A falling count tells your team your body needs a pause or a dose adjustment before it becomes a problem. The same test also confirms you are well enough for surgery or the next cycle of treatment.

What the numbers mean: Low red cells (anaemia) can cause tiredness and breathlessness. Low platelets affect clotting and bruising. Your team compares each result to your own baseline, not just to the reference range printed on the form.

White cell count (WBC) and neutrophilsBlood

What it measures: The number of white blood cells, the immune cells that fight infection, with a breakdown of the main types including neutrophils.

Why it is repeated: A low white cell count, especially low neutrophils (neutropenia), means your defences are down and an infection could take hold quickly. This is the number your team checks before every chemotherapy cycle.

What the numbers mean: If your neutrophils fall below a certain level, treatment may be delayed by a few days or you may be given a medication to boost your counts. A fever when your counts are low is an emergency. Call your team straight away.

Liver function tests (LFTs)Blood

What it measures: A group of enzymes and proteins (ALT, AST, ALP, GGT and bilirubin) that show how well your liver and bile ducts are working.

Why it is repeated: Many treatments are processed by the liver, and biliary and HPB cancers can affect bile flow. Rising levels can signal inflammation or a blockage before you feel any symptoms. Abnormal LFTs are also often the first clue that leads to a scan at diagnosis.

What the numbers mean: Mild rises are common and often settle on their own. Your team watches the pattern and may adjust treatment if levels climb steadily.

Kidney function (creatinine and eGFR)Blood

What it measures: Creatinine, a waste product your kidneys clear, and eGFR, an estimate of how well they are filtering.

Why it is repeated: Several chemotherapy drugs and contrast dyes need good kidney function to be given safely. Your team checks this before each cycle and before scans.

What the numbers mean: A rising creatinine or falling eGFR means your kidneys are under strain. Often this is managed with hydration or a dose adjustment.

Electrolytes (sodium, potassium, calcium, magnesium)Blood

What it measures: The minerals your heart, nerves and muscles need to work, which must stay in a narrow range.

Why it is repeated: Vomiting, diarrhoea, poor intake and some treatments can all push these out of balance. Low magnesium and potassium are common during chemotherapy.

What the numbers mean: Most imbalances are fixed simply, with diet, supplements or an infusion. Your team corrects them before they cause symptoms.

Albumin and proteinBlood

What it measures: Albumin, the main protein in your blood and a marker of your nutritional status.

Why it is repeated: Upper GI and HPB cancers, and their treatment, can make eating difficult. A falling albumin is an early sign your body is not getting enough nutrition to heal and recover.

What the numbers mean: A low albumin prompts a dietitian review and nutrition support, from supplements to a feeding tube if needed. Keeping you nourished is a core part of treatment, not an afterthought.

Coagulation profile (INR and APTT)Blood

What it measures: How quickly your blood clots.

Why it is repeated: The liver makes the proteins that control bleeding, so if liver function dips, clotting can slow. This is checked before any procedure or surgery, and if your LFTs are abnormal.

What the numbers mean: A raised INR means your blood is clotting more slowly than ideal. Your team corrects this before procedures to keep you safe.

Do not read your results alone. A monitoring form is full of numbers that mean very little on their own, and the reference ranges printed beside them are for healthy people, not for someone in treatment. Bring your results to your next appointment, or ask your clinical nurse consultant to talk you through them. Your team reads them in context, and that context is everything.

While you wait

What happens at an MDT meeting.

After your tests, you may be told your case is "going to MDT", and then asked to wait. The wait between tests and a plan is often the hardest part of the whole journey. Knowing what is actually happening in that room can make it easier to carry.

An MDT (multidisciplinary team) meeting is where your case is reviewed by every relevant specialist at once, in one room, rather than one doctor at a time in separate clinics. It is the standard of care for upper GI and HPB cancers in Australia, and it means the plan you are given has already been stress-tested by the people who will deliver it.

Who is in the room.

HPB / upper GI surgeon

Asks: can this be removed safely, and how? Describes the operation that would be needed.

Medical oncologist

Asks: what can chemotherapy add, before or after surgery? Reviews the evidence for your specific cancer.

Radiologist

Reads your scans to the room and describes exactly where the cancer is and what it involves.

Pathologist

Explains what your biopsy or surgical sample shows under the microscope, including the grade and any biomarkers.

Radiation oncologist

Advises whether radiotherapy has a role, either to shrink the tumour before surgery or to control symptoms.

Clinical nurse consultant

Your consistent contact. Takes notes on the discussion and makes sure the plan is explained to you clearly afterwards.

And sometimes

A genetic counsellor, an interventional radiologist, a palliative care specialist, or your GP's perspective, whenever they add something your case needs.

How a recommendation gets made.

1

Your case is booked onto the meeting list

Your scans, pathology results and history are gathered and prepared so the team has everything in front of them.

2

The specialists review your case together

The radiologist walks through your imaging, the pathologist through your biopsy, and each specialist gives their view of the options.

3

Options are debated openly

Surgery first, chemotherapy first, or a combination. The team weighs the evidence for your specific cancer type and stage, and for your overall health.

4

A recommended plan is agreed and recorded

The team settles on a recommendation and documents the reasoning, so every doctor involved is working from the same page.

5

Your doctor explains it to you

The recommendation goes to your treating doctor, who walks you through it at your next appointment and answers your questions. You can ask to see the MDT summary.

A word about the wait

Two weeks feels like forever. Here is what it actually is.

The gap between your last test and your treatment plan is not a gap in your care. It is the time your case spends being reviewed by a whole room of specialists so that the plan you are given is the best one they can build. If the waiting is becoming unbearable, tell your clinical nurse consultant. Being honest about how it is affecting you is part of your care too.

Know what’s normal, know what’s not

Side effects, and when to call.

Most side effects of treatment are expected, manageable, and temporary. But a few need urgent attention. The trick is knowing the difference, and acting early. This section separates the everyday from the urgent, and tells you what helps for each.

Call now, don’t wait.

These need urgent attention, day or night. Call your treatment team’s emergency number, or go to the nearest emergency department. If you are not sure whether it counts, call anyway. That is what the number is for.

  • A fever of 38°C or higher, or chills and shaking, especially during chemotherapy
  • Vomiting blood, or stools that are black and tarry
  • Severe or rapidly worsening abdominal pain
  • New yellowing of your skin or the whites of your eyes
  • Difficulty breathing, or chest pain
  • Unable to keep fluids down for more than 24 hours
  • Confusion, severe drowsiness, or difficulty waking
  • A surgical wound that is increasingly red, swollen, painful, or leaking

The common ones, and what helps.

Nausea and vomiting

Common with chemotherapy and some targeted drugs, and often worst in the first days after a cycle.

What helps: Take anti-nausea medication regularly as prescribed, not just when you feel sick. Small, frequent, bland meals; ginger; fresh air; avoiding strong cooking smells.

Call if: You cannot keep fluids down, or you vomit blood.

Tiredness that doesn’t lift

Cancer-related fatigue is not ordinary tiredness and does not always improve with rest. It is one of the most common and least talked-about side effects.

What helps: A short daily walk, pacing your day, planning rest before you are exhausted, and being honest with your team about how much it is affecting you.

Call if: It comes on suddenly, or you feel dizzy, faint, or breathless.

Diarrhoea

Can be caused by chemotherapy, targeted drugs, or surgery that changes how your bowel works.

What helps: Plenty of fluids, a low-fibre diet while it settles, and anti-diarrhoeal medication your team has okayed. Keep a record of frequency to share with them.

Call if: More than four to six episodes a day, blood in it, or you feel light-headed.

Constipation

Often a side effect of pain medication, anti-nausea drugs, or reduced activity after surgery.

What helps: Fluids, gentle movement, fibre if you tolerate it, and a laxative routine if your team recommends one. Do not strain after abdominal surgery.

Call if: Severe abdominal pain, vomiting, or no bowel movement for several days.

Mouth sores and dry mouth

Chemotherapy can irritate the lining of the mouth, causing sores, dryness, or a changed sense of taste.

What helps: Soft, cool foods; gentle brushing; salt-and-bicarbonate mouth rinses; avoiding acidic, spicy, or very hot food and alcohol-based mouthwashes.

Call if: Sores make eating or drinking difficult, or you develop a fever.

Loss of appetite and taste changes

Food may taste metallic or bland, and hunger may disappear. This is common and usually temporary, but nutrition matters for recovery.

What helps: Eat when you can rather than on a schedule; small frequent meals; try new flavours; use plastic cutlery if food tastes metallic. A dietitian can be a game-changer.

Call if: You are losing weight or have eaten very little for several days.

Tingling or numbness (neuropathy)

Some chemotherapy drugs affect the nerves, causing tingling, numbness, or clumsiness in the hands and feet.

What helps: Tell your team early, even if it seems minor. Dose adjustments can prevent it worsening. Protect your hands from heat and cold, and take care with sharp objects.

Call if: It is getting worse, or affects buttoning clothes, walking, or balance.

Skin changes and rash

Some treatments cause dryness, itching, rash, or sensitivity to the sun. Targeted therapies in particular can affect the skin.

What helps: Fragrance-free moisturiser, gentle soap, high-SPF sunscreen, and loose clothing. Your team can prescribe creams that work better than over-the-counter options.

Call if: A rash is blistering, spreading quickly, or comes with a fever.

Low blood counts and infection risk

Chemotherapy temporarily lowers the white cells that fight infection. Your team checks this before every cycle, but you are the one living between visits.

What helps: Frequent hand washing, avoiding people who are unwell, careful food handling, and knowing your temperature. Report any sign of infection promptly.

Call if: A fever of 38°C or higher, or chills. This is the single most important one.

Difficulty swallowing

Common with oesophageal cancers and their treatment, and sometimes after surgery or radiotherapy to the area.

What helps: Soft, moist foods; small bites; eating upright and staying upright after meals. A speech pathologist or dietitian can teach techniques that make a real difference.

Call if: You cannot swallow liquids, you are choking, or you are losing weight.

Eating when it’s hard.

For upper GI and HPB cancers, nutrition is not a side issue. Digestion is exactly what these organs do, so treatment can change how you eat in real ways. None of this is a failing on your part, and almost all of it has a solution. Here are the ones you are most likely to meet.

Pancreatic enzymes

After pancreatic surgery, your body may not release enough enzymes to digest fat, causing bloating, pale stools, or weight loss. Enzyme capsules taken with meals replace them. If you have been prescribed them and they are not working, tell your team; the dose often needs adjusting.

Small, frequent meals

After stomach or oesophageal surgery, a normal-sized meal may be too much. Six small meals a day, eaten slowly and chewed well, usually work better than three large ones. Drinking between meals rather than with them can also help.

Feeding tubes

If you cannot keep up with your nutrition needs by mouth, a feeding tube can carry the load while you recover. A nasogastric tube goes through the nose and is usually short-term; a PEG tube goes directly into the stomach and can stay longer. Both are common, and neither is a step backwards.

Seeing a dietitian

A dietitian who knows upper GI and HPB care is one of the most under-used resources available to you. Ask for a referral early, not as a last resort. They can tailor everything above to your surgery, your treatment, and your actual food preferences.

Every treatment is different. The side effects above are common across upper GI and HPB treatments, but your specific drugs and surgery carry their own profile. Your team will tell you which ones to expect and give you a written plan. Keep their emergency number somewhere obvious, and use it without hesitation when you need to.

Learn the map

Who's who in the hospital.

A hospital is full of titles that are never explained. Knowing who does what helps you direct your questions to the right person, and understand who is in the room when the team comes around.

Consultant (specialist)

The senior doctor in charge of your care. They make the final decisions, perform your operation, and set your treatment plan. In Australia they may also be called a specialist or a visiting medical officer.

Fellow

A fully qualified surgeon doing one or two extra years of sub-specialty training, often specifically in HPB or upper GI surgery. Very experienced, and works closely with the consultant.

Registrar

A doctor training to become a specialist. Often the first doctor you meet on the ward, reviews you daily, and usually knows the day-to-day details of your case better than anyone.

Resident / intern

Junior doctors in their first years after medical school. They handle the everyday ward work, all under supervision.

Clinical nurse consultant / coordinator

Your consistent point of contact across the whole journey, from diagnosis through treatment and follow-up. Often the best person to call with questions between appointments.

Allied health

Dietitians, physiotherapists, social workers and psychologists who support your recovery. Nutrition support in particular is a big part of upper GI and HPB care, so a dietitian will likely be involved early.

Places and routines you will meet.

Ward round

The daily visit where the whole team walks the ward and reviews each patient together. It is a good time to ask a question, or to ask the nurse to pass one on if the round moves quickly.

Day oncology unit

Where you go for chemotherapy and regular blood tests. You are monitored for a few hours and then go home the same day. You do not stay overnight.

Surgical ward

Where you stay after an operation while you recover. The length of stay depends on the operation, and your team will give you a realistic expectation beforehand.

Admission process

For a planned operation you will usually be admitted on the morning of surgery. You will be asked about allergies, medications and fasting, and you will meet the anaesthetist before going to theatre. Bring a list of your medications.

Bigger than one person

Family, genes and inherited risk.

A cancer diagnosis is never just about one person. Some of these cancers run in families, and knowing whether yours does can change both your treatment and your relatives' screening. Here is the plain-language version.

Most upper GI and HPB cancers are sporadic, meaning they happen by chance and are not passed down. But a small number are hereditary, caused by an inherited change in a gene. Knowing the difference matters for two reasons: it can open up better treatment options for you, and it tells your family whether they should be screened earlier.

Who should consider genetic testing. Testing is usually suggested when there are several close relatives with the same or related cancers, when a cancer was diagnosed at a young age, when a known gene change already runs in the family, or when certain patterns appear together, such as pancreatic cancer alongside breast or ovarian cancer. Your oncologist or GP can refer you.

What a genetic counsellor does. They explain what testing can and cannot tell you, help you decide whether to have it, walk you through the result whatever it is, and coordinate testing for relatives if needed. You do not need to have any answers before you see one. Asking for a referral is a reasonable first step.

BRCA, in plain English. BRCA1 and BRCA2 are genes that help repair damaged DNA. When they carry an inherited change, that repair system does not work as well, and the risk of several cancers rises. A BRCA result is not just about risk: it can also make you eligible for a class of targeted drugs called PARP inhibitors, which work particularly well in cancers with this weakness.

What a result means for your family. If a change is found, close relatives can have a simple blood test to see whether they carry the same change. This is called cascade testing. It is information, not a sentence, and it gives people the chance to be screened earlier and act sooner.

Why testing can change your care

Matching the treatment to the tumour.

For several upper GI and HPB cancers, a specific test result can open the door to a treatment that would otherwise not be offered. Examples your team may discuss include:

1

HER2 testing in stomach and junction cancers

Tumours that overproduce the HER2 protein may respond to targeted drugs such as trastuzumab, added to chemotherapy. HER2 testing is now standard for advanced stomach and gastro-oesophageal junction cancers.

2

MSI and mismatch repair testing

Tumours described as MSI-H or mismatch repair deficient have a particular weakness that immunotherapy can exploit. This test is increasingly done across upper GI cancers because a positive result can make immunotherapy an option.

3

BRCA testing in pancreatic cancer

Some pancreatic cancers carry a BRCA1 or BRCA2 change, either inherited or found in the tumour. For selected patients, this can open the door to a class of targeted drugs called PARP inhibitors.

4

FGFR2 and IDH1 in bile duct cancer

Cholangiocarcinoma is one of the cancers where tumour profiling has moved fastest. Changes in the FGFR2 or IDH1 genes can, in some cases, be matched to targeted therapies available through trials or special access.

5

Broader panels and clinical trials

Comprehensive genomic profiling looks at many genes at once and can reveal rarer targets, such as NTRK fusions, that have treatments approved across cancer types. Results can also match you to clinical trials.

Not every tumour has a targetable change, and not every result leads to a different treatment. But testing is the only way to know, and it is a reasonable and increasingly routine thing to ask about.

Take this with you

Questions to ask, appointment by appointment.

Patients freeze in the room. It is completely normal, and it happens to nearly everyone. A written checklist you bring with you changes the dynamic: you leave with the answers you actually need, not just the ones you happened to think of. Tick them off as you go, and print the list for your next visit.

A note on this information. This page is general education, not medical advice. Every cancer and every person is different. Always discuss your diagnosis, testing and treatment options with your own care team, who know the details of your case. If you are unsure whether genetic testing is right for you, ask your oncologist directly.

Your dictionary

The glossary, grouped by the moment you'll hear it.

A dictionary in alphabetical order is how a reference book works. This one is organised the way your journey is: by the conversation you just had. Pick the moment you are in, or search for the exact word below, and the plain-language meaning is right there.

Showing 151 of 151 terms
At diagnosis 24 terms
Adenocarcinoma
The most common cancer type in this region. Starts in the glandular cells lining the inside of an organ.
Benign
Not cancer. A benign growth does not invade nearby tissue or spread.
Carcinoma kar-sin-oh-muh
A cancer that begins in the cells lining an organ. Most upper GI and HPB cancers are carcinomas.
Curative intent
Treatment given with the goal of removing or destroying all of the cancer.
Gastroscopy
A procedure where a flexible tube with a camera examines the oesophagus, stomach and duodenum.
Grade
How abnormal the cancer cells look under the microscope. A measure of how quickly the cancer tends to grow.
HPB (hepatopancreatobiliary) hep-uh-toh-pan-kree-uh-toh-bil-ee-air-ee
The liver, pancreas, bile ducts and gallbladder, treated by surgeons as one connected region.
ICG fluorescence
A dye used during surgery that lights up under near-infrared light, helping surgeons see blood supply and bile ducts clearly.
Incidental finding
Something unexpected found during a scan or procedure done for another reason. Many early cancers are found this way.
Localised
Cancer that is still confined to the organ where it began.
Locally advanced
Cancer that has grown into nearby tissue or lymph nodes but has not spread to distant organs.
Malignant
Cancerous. Able to invade nearby tissue and spread to other parts of the body.
MDT (multidisciplinary team)
A group of specialists who meet regularly to review your case and agree on the best treatment plan together.
Multidisciplinary team (MDT) mul-tee-dis-uh-plin-air-ee
The group of surgeons, oncologists, radiologists, pathologists and nurses who meet to plan your care together.
Oncologist on-kol-uh-jist
A doctor who specialises in treating cancer, usually with drugs (medical oncologist) or radiotherapy (radiation oncologist).
Palliative pal-ee-uh-tiv
Care focused on controlling symptoms and keeping quality of life high. It can be given alongside active treatment, not only near the end of life.
Primary cancer
The original cancer, named for where it started. A pancreatic cancer found in the liver is still pancreatic cancer.
Prognosis
The likely course and outlook of a cancer. It is a statistical guide, never a prediction for one person.
Recurrence
Cancer that has come back after a period of remission.
Remission
A period when the cancer has responded to treatment and signs of it have reduced or disappeared.
Secondary cancer (metastasis)
Cancer that has spread from where it started to another part of the body. Also called metastatic disease.
Stage
A description of how far a cancer has grown and spread, usually stages 1 to 4. Guides treatment decisions.
Tumour
A mass of abnormal cells. A tumour can be benign or malignant.
Upper GI
The upper part of the digestive tract: the oesophagus, stomach and the first part of the small bowel (duodenum).
On your pathology report 28 terms
Biomarker bye-oh-mar-ker
A measurable sign in the tumour, such as a protein or gene change, that helps predict which treatments will work.
Biopsy
A small tissue sample taken for testing. Most cancers are confirmed this way, though some, such as liver cancer in a cirrhotic liver, can be diagnosed from scans alone.
Copy number change (CNV) see-en-vee
An extra or missing copy of a gene inside cancer cells. Some genomic tests report these alongside mutations, because they can also point to targeted treatments.
Core biopsy
A biopsy taken with a hollow needle that removes a small cylinder of tissue.
Differentiation
How much cancer cells resemble normal cells. Well differentiated looks closer to normal; poorly differentiated looks very abnormal.
Endoscopic biopsy
A biopsy taken through an endoscope during a gastroscopy, EUS or ERCP.
Fine needle aspiration (FNA)
A biopsy using a very thin needle to draw out cells, often guided by endoscopic ultrasound.
Gene fusion fyoo-zhun
When two genes join together abnormally, creating a new instruction that can drive cancer growth. Fusions such as FGFR2 and NTRK can be matched to targeted drugs.
HER2 her-two
A protein found on some stomach and oesophageal cancers. If present, targeted drugs such as trastuzumab may be used.
IDH1 and FGFR2 eye-dee-aych-wun, eff-gee-eff-ar-too
Genes that can carry changes in some bile duct cancers. Testing for them can open up targeted treatment or clinical trial options.
Immunohistochemistry
Special stains used on the sample to identify proteins such as HER2 or MMR. Helps guide targeted treatment.
Liquid biopsy (ctDNA) see-tee-dee-en-ay
A blood test that looks for fragments of tumour DNA circulating in the bloodstream. An option for genomic testing when a tissue sample is not available.
Lymph node
A small filter in the immune system. Cancer often spreads to nearby lymph nodes first.
Lymphovascular invasion
Cancer cells seen inside tiny blood vessels or lymph channels in the sample.
Margin
The edge of the removed tissue. A clear (R0) margin means no cancer cells at the cut edge.
MMR / MSI em-em-ar, em-es-eye
Mismatch repair testing. Shows whether a tumour has a particular DNA repair fault that can point toward immunotherapy.
Next-generation sequencing (NGS) en-jee-ess
The laboratory method used to read many genes at once from a tumour sample, to find changes that may respond to targeted treatments or clinical trials. It is the technology behind most genomic profiling panels.
Pathologist puh-thol-uh-jist
The doctor who examines tissue under the microscope and writes your pathology report.
PD-L1 pee-dee-el-one
A protein measured on some tumours that helps predict response to immunotherapy.
Perineural invasion
Cancer cells seen wrapping around small nerves in the sample.
Programmed death-ligand 1 (PD-L1)
A protein on cancer cells that helps them hide from the immune system. Testing its level can guide immunotherapy decisions.
R0 / R1
R0 means the margins are clear of cancer. R1 means cancer cells were seen at the cut edge.
Microsatellite instability (MSI)
A DNA repair defect inside the tumour. Cancers with high MSI may respond particularly well to immunotherapy.
Somatic mutation soh-mat-ik
A gene change that occurred in the cancer itself, not one you were born with. Somatic mutations are what tumour profiling looks for.
Specimen
The tissue sample sent to the lab, whether from a biopsy or from surgery.
TNM
The staging system: T for tumour depth, N for lymph node involvement, M for spread to distant sites.
Tumour board
Another name for the MDT meeting where your scans, pathology and history are reviewed together to plan care.
Tumour mutational burden (TMB) tee-em-bee
A count of how many gene changes a tumour carries. A high TMB can point toward immunotherapy, because heavily mutated tumours are easier for the immune system to recognise.
Around treatment 29 terms
Ablation
A treatment that uses heat, cold or electrical energy to destroy tumour tissue without open surgery.
Active surveillance
Monitoring a slow-growing condition, such as certain pancreatic cysts, with regular scans rather than immediate surgery.
Adjuvant
Treatment given after surgery, to reduce the risk of the cancer returning.
Biliary drainage
A procedure to relieve a blocked bile duct, often by placing a stent, so bile can flow again.
Chemoradiotherapy kee-moh-ray-dee-oh-ther-uh-pee
Chemotherapy and radiotherapy given together, often before surgery for oesophageal cancer.
Chemotherapy
Anti-cancer drugs that circulate through the whole body.
Clinical trial
A research study testing a new treatment. Can offer access to the next generation of therapies.
Cycle
One round of chemotherapy: treatment on certain days followed by a rest period. Treatment is counted in cycles.
Distal pancreatectomy dis-tul pan-kree-uh-tek-tuh-mee
Surgery to remove the body or tail of the pancreas.
Embolisation em-boh-lie-zay-shun
A procedure that blocks the blood supply to a liver tumour, sometimes combined with chemotherapy or radiation beads.
Endoscopic mucosal resection (EMR)
Removal of very early-stage tumours or pre-cancerous tissue through an endoscope, without external incisions.
FOLFIRINOX fol-fee-ree-noks
A combination chemotherapy regimen commonly used for pancreatic cancer.
Gastrectomy gas-tek-tuh-mee
Surgery to remove part (partial) or all (total) of the stomach.
Gemcitabine jem-sit-uh-been
A chemotherapy drug often used for pancreatic and biliary cancers.
Hepatectomy hep-uh-tek-tuh-mee
Surgery to remove part of the liver.
Immunotherapy
Treatments that help your own immune system recognise and attack cancer cells.
Keyhole surgery
Surgery done through several small cuts using a camera and instruments (laparoscopic or robotic), rather than one large incision.
Multimodal therapy
Combining two or more types of treatment, usually chemotherapy, radiation and surgery, for the best chance of cure.
Neoadjuvant
Treatment given before surgery, usually to shrink the tumour.
Oesophagectomy oh-sof-uh-jek-tuh-mee
Surgery to remove part or all of the oesophagus, often with the stomach pulled up to replace it.
Patient-reported outcomes (PROs)
Information about symptoms and quality of life reported directly by you, not interpreted by a clinician.
Portal vein
The main vein carrying blood from the gut to the liver. Whether a tumour touches it affects whether surgery is possible.
Prehabilitation
A program of exercise, nutrition and psychological support before major treatment, to help you cope better with it and recover faster.
Radiotherapy
High-energy beams targeted at the tumour.
Resectable
Able to be removed by surgery.
Stent
A small tube placed in a blocked bile duct or oesophagus to keep it open.
Targeted therapy
Drugs that block specific molecules a cancer needs to grow. Only work if the tumour carries the target.
Unresectable
Not able to be removed by surgery, usually because of where it is or how far it has spread. Other treatments still apply.
Whipple (pancreaticoduodenectomy) whip-ul, pan-kree-uh-toh-doo-oh-dee-neh-dek-tuh-mee
A major operation to remove the head of the pancreas and nearby structures. The standard operation for cancers in that location.
Radiology & scans 23 terms
Angiography an-jee-og-ruh-fee
Imaging of the blood vessels, used to check whether a tumour involves major arteries or veins.
CA 19-9
A blood protein that can be elevated in pancreatic and biliary cancers. Used alongside scans to monitor response, but NOT a screening test on its own.
Contrast
A dye given by injection or by mouth that makes organs and blood vessels show up more clearly on scans.
CT scan
Detailed X-ray images built into a 3D picture. The main scan for diagnosis and staging.
CT-guided biopsy
A biopsy where the needle is positioned using a CT scan, often used for liver or pancreatic samples.
Diagnostic laparoscopy lap-uh-ros-kuh-pee
A keyhole operation to look inside the abdomen directly, used to check for tiny spread that scans can miss before major surgery. Also called staging laparoscopy.
Doppler ultrasound
An ultrasound that shows blood flow in vessels, used to check the portal vein and liver vessels.
Endoscopy (gastroscopy)
A thin camera passed through the mouth to look at the oesophagus and stomach.
ERCP
An endoscope used to image the bile ducts and often to place a stent.
EUS (endoscopic ultrasound)
An ultrasound probe on an endoscope, so the scan happens from inside, right next to the pancreas.
Fluoroscopy floor-os-kuh-pee
Real-time X-ray imaging used during some procedures to guide instruments.
Functional imaging
Scans that show not just structure but also how tissues are working. PET and HIDA scans are examples.
HIDA scan
A nuclear medicine scan that traces bile flow from the liver through the bile ducts and into the bowel.
Interval imaging
Scans taken at regular set times after treatment to check for any change, rather than waiting for symptoms.
Interventional radiologist
A doctor who uses imaging to guide needles and tubes for biopsies, drains and stents.
Liver ultrasound
A quick, radiation-free scan using sound waves, often the first test for the liver and bile ducts.
MRCP
A special MRI that pictures the bile ducts and pancreatic duct.
MRI
Detailed images made with magnets and radio waves, without radiation.
MRI liver (hepatobiliary MRI)
A specialised MRI with a contrast agent taken up by liver cells, used to characterise liver lesions.
PET scan
A scan that shows where cells are most active, used to check for spread.
Radiologist ray-dee-ol-uh-jist
The doctor who reads your scans and writes the imaging report.
Radiomics
Computer analysis of scan images to detect patterns the human eye might miss, increasingly used in research and clinical trials.
Ultrasound-guided biopsy
A biopsy where the needle is positioned using an ultrasound scan.
Monitoring & blood tests 25 terms
Albumin
A protein made by the liver that keeps fluid in your blood vessels and carries substances around the body. A low level can be a sign of poor nutrition or liver strain.
Alkaline phosphatase (ALP)
An enzyme found in the liver, bile ducts and bone. Rising levels can point to a blockage or disease progression.
Anaemia uh-nee-mee-uh
A lower-than-normal level of red blood cells or haemoglobin, causing tiredness and breathlessness.
APTT
Activated partial thromboplastin time. Another measure of how your blood clots, often checked alongside INR before surgery or while you are on blood thinners.
Bilirubin bil-ih-roo-bin
A yellow pigment made when old red blood cells are broken down. A high level causes jaundice and can signal a blocked bile duct.
CA19-9 see-ay-nine-teen
A tumour marker blood test most often used for pancreatic and biliary cancers. It is a trend to watch over time, not a diagnosis on its own.
CEA (carcinoembryonic antigen)
A blood protein that can be elevated in several GI cancers. Used for monitoring, not diagnosis.
CEA see-ee-ay
Carcinoembryonic antigen. A tumour marker blood test used for some stomach and bowel cancers.
Complete blood count (CBC)
A routine blood test that counts your red cells, white cells and platelets. Important before and during chemotherapy.
CRP (C-reactive protein)
A blood test that measures inflammation in the body.
eGFR and creatinine
Creatinine is a waste product your kidneys filter out, and eGFR is a number calculated from it that estimates how well your kidneys are working. A falling eGFR means the kidneys are under strain, which can affect how some treatments are dosed.
Electrolytes
Minerals in your blood that keep your heart, muscles and nerves working, including sodium, potassium, calcium and magnesium. Treatment and dehydration can push them out of range.
FBC (full blood count)
A single blood test that measures your red blood cells, white blood cells and platelets. It is the most common monitoring test, repeated at nearly every visit to check that your blood can carry oxygen, fight infection and clot properly.
Febrile neutropenia feb-rile new-troh-pee-nee-uh
A low white cell count together with a fever. It is an emergency during chemotherapy and needs urgent antibiotics.
Follow-up (surveillance)
The schedule of scans and blood tests after treatment ends, to watch for any sign of the cancer returning.
Haemoglobin
The protein in red blood cells that carries oxygen around your body. A low level is called anaemia and can cause tiredness and breathlessness.
INR
International Normalised Ratio. A measure of how quickly your blood clots. A higher INR means slower clotting, checked before surgery and watched closely if you are taking blood-thinning medication.
Jaundice jon-diss
Yellowing of the skin and eyes caused by a build-up of bilirubin, often from a blocked bile duct.
LFTs (liver function tests)
A group of blood tests that show how well your liver and bile ducts are working. They include bilirubin and the enzymes ALT, AST and ALP. Rising levels can signal a blockage or inflammation that needs attention.
Neutropenia new-troh-pee-nee-uh
A low level of neutrophils, the infection-fighting white cells, raising the risk of infection.
Neutrophils
A type of white blood cell that is first to fight infection. Chemotherapy can lower their number, so your team checks them before each cycle. A low count is called neutropenia and may mean treatment needs a short pause.
Performance status
A score from 0 to 4 of how well you can carry out daily activities, used to judge whether treatment is tolerable.
Platelets
Small cell fragments that help your blood clot and stop bleeding. A low platelet count, common during chemotherapy, can cause easy bruising or bleeding.
Tumour marker
A substance in the blood, such as CA19-9 or CEA, that can rise with some cancers and is tracked over time.
White blood cells (WBC)
The cells that fight infection, measured on a full blood count.
Family risk 22 terms
BRCA1 / BRCA2
Genes that repair DNA. Inherited changes in them raise the risk of several cancers and can open up targeted treatments.
BRCA2
A gene that normally protects against cancer. Inherited changes in BRCA2 raise the risk of pancreatic, breast and other cancers.
Cascade testing
Testing relatives one generation at a time after a gene change is found in the family.
CDH1 see-dee-aitch-one
A gene linked to hereditary diffuse gastric cancer. Families with several stomach cancers may be tested for it.
Familial pancreatic cancer
A term used when two or more close relatives have had pancreatic cancer, suggesting a possible inherited tendency.
Familial risk
A higher-than-average risk because several relatives have had the same or related cancers, even without a single identified gene.
Family history
The record of cancers in your blood relatives, used to judge whether genetic testing is appropriate.
Gene mutation (variant)
A change in a gene. Some changes raise cancer risk; many are harmless.
Genetic counsellor
A specialist who explains genetic testing, supports your decision, and coordinates family testing.
Genetic test
A blood or saliva test that looks for inherited gene changes that raise cancer risk.
Germline jerm-line
A gene change present in every cell of the body and able to be passed to children. Different from changes found only in the tumour.
Germline testing
Testing DNA from a blood or saliva sample, not the tumour, to see if you were born with a gene change that raises cancer risk.
Hereditary
Passed down through a family via genes. Only a small number of these cancers are hereditary.
Lynch syndrome
An inherited condition that raises the risk of several cancers, including stomach and biliary cancers.
PALB2 pal-bee-two
A gene linked to pancreatic cancer risk.
Peutz-Jeghers syndrome puts-ye-gers
A rare inherited condition causing polyps and a higher risk of several GI cancers.
Risk-reducing surgery
An operation to remove an organ at very high risk before cancer develops, considered in some inherited syndromes.
Screening
Regular checks for people at higher risk, to find cancer early or before it develops.
Somatic soh-mat-ik
A gene change found only in the tumour, not inherited and not passed on.
Sporadic
Happening by chance, not inherited. Most upper GI and HPB cancers are sporadic.
STK11
A gene linked to Peutz-Jeghers syndrome. Inherited changes raise the risk of several GI cancers, including pancreatic.
Tumour profiling
Testing the cancer's own DNA for targetable changes. Different from testing the genes you were born with.
No terms match your search. Try a different word, or switch the filter above back to “All terms”.
For surgeons, nurses & trainees

Education for the profession.

Education at The HOPE Fund runs in both directions. As well as informing patients, we invest in training the next generation of upper GI and HPB surgeons and the wider care team.

Many of our research projects run in partnership with St Vincent's Hospital, a teaching hospital where registrars on accredited surgical training programs with RACS are supervised and trained.

Surgical fellowships with global reach.

The HOPE Fund supports surgical training through fellowships, 18-month programs which provide specialty skills and contribute to higher global standards in surgical practice. Dr Keith Dindi, from rural Kenya, is one of the first graduates and is qualified as both a general and cardiothoracic surgeon.

To facilitate training, we work with OESO to ensure worldwide collaboration and high quality training. With Melbourne as a key centre to offer training, the program provides Dr Dindi with the necessary skillsets through six months of rotations in cardiac surgery, thoracic surgery and general / vascular surgery.

The inaugural scholarship program

A scholarship that came home.

With our support, surgeon Mr Matthew Read completed a fellowship with a focus on robotic surgery at the University Medical Center in Utrecht, the Netherlands, and continued his research into oesophageal cancer. Since returning to St Vincent's as a consultant surgeon, Matthew has established key international collaborations and furthered local research interests.

“The scholarship has given me unparalleled opportunities to learn from internationally renowned experts within my surgical specialty and to collaborate with leading researchers to optimise treatments for oesophageal cancer.”Matthew Read

Sources: Cancer Australia, oesophageal, stomach, liver and pancreatic cancer pages; Cancer Council Australia, cancer type information for oesophageal, stomach, liver and pancreatic cancer; Cancer Council Australia, Optimal Care Pathway for people with oesophagogastric cancer (2nd edition) and Optimal care pathway for people with biliary cancer; eviQ, cancer treatment protocols; National Cancer Institute, PDQ cancer treatment summaries.